Corsano Health
Corsano Health, based in The Hague, makes the CardioWatch, a certified medical wrist wearable that measures up to 10 vital parameters continuously, including heart rate, respiratory rate, oxygen saturation, skin temperature, cuffless blood pressure, activity and sleep. Data streams to the Corsano Cloud and a hospital dashboard, where Cor-EWS, its early warning score, uses personalized baselines, statistical models and machine learning to flag clinical deterioration on general wards and after discharge, with versions offering more or less machine learning to balance interpretability.
The CardioWatch is FDA cleared and CE marked under the EU MDR, and in July 2026 the FDA cleared its sleep wake monitoring function. Medtronic distributes it exclusively in the US for hospital and hospital to home use, after Medtronic launched it in Western Europe in 2025, and Foch Hospital in Paris and Imelda Hospital in Antwerp are named hospital users. The same device serves remote patient monitoring, decentralized clinical trials, pharma studies and academic research, with raw data access for partners building their own algorithms. Peter Stas is chief executive.
Capability Axes
An AI Health Index grade measures what a buyer can verify from public sources on the date shown. It is not a rating of how good the product is. A vendor can build an excellent system and grade low on an axis because it publishes nothing an outsider can check. How grades read
Models sit at two layers. Vital signs are computed from the wristband's sensors by algorithms such as cuffless blood pressure, developed since 2019 on arterial line and ambulatory blood pressure data from more than 500 patients, and Cor-EWS turns those streams into an early warning score from personalized baselines and machine learning that flags and predicts deterioration.
The device also sells as a continuous vital signs monitor and a research data source, with raw data access for partners, which carries value without the predictive layer.
Cor-EWS scores vital parameters continuously and alerts healthcare workers when a patient's risk rises, so clinicians act on the alert; hospitals can also run conventional early warning scores on the same data. For CAR T cell therapy, Corsano describes using its predictive scores to support discharging lower risk patients to ambulatory monitoring.
Alert thresholds, escalation paths and how a clinician overrides a score are not described.
Cor-EWS is described in some detail: personalized baselines for pulse rate, heart rate variability, oxygen saturation, respiratory rate and other parameters, updated as the patient's status and treatment change, analysis of how the parameters move together, and statistical models and machine learning, offered in versions with different amounts of machine learning to balance interpretability. The cuffless blood pressure algorithm's training data is characterized as arterial line and ambulatory readings from more than 500 patients.
Model versions and update practice are not published.
The algorithms are Corsano's own: the cuffless blood pressure model has been in development since 2019 and Cor-EWS is described as Corsano's early warning system, and the cloud runs on Amazon Web Services. Data also flows outward by design, since research and pharma partners receive raw data to build their own algorithms.
No subprocessor list beyond AWS is published.
The cuffless blood pressure algorithm was tested to ISO 81060-2:2019 and the AAMI, ESH and ISO universal standard for blood pressure devices, on development data from more than 500 patients, and the CardioWatch carries FDA clearances and CE marking under the EU MDR. Corsano publishes a publications library and white papers, and Foch Hospital and Imelda Hospital are named hospital users.
No outcome results for Cor-EWS, such as earlier detection or fewer adverse events, are reported.
Production data is stored on Amazon Web Services across separated data clusters replicated in multiple availability zones, with encryption at every layer, OAuth and JWT authentication and automated security tests on each block of the infrastructure. Corsano describes compliance with GDPR and HIPAA and offers research partners raw data access to develop their own algorithms.
How long patient data is kept, and whether hospital data trains Corsano's models, is not stated.
Corsano describes its cloud as HIPAA compliant and runs on AWS as an AWS business associate, with a GDPR program, a data protection officer and a privacy policy on its site. US hospitals buy through Medtronic.
No statement that Corsano signs business associate agreements with its own customers, and no agreement, is published.
A security page describes the controls: AWS hosting with access control lists, firewalls, anti malware, TLS and VPN, separated and replicated data clusters, encryption at every layer, automated security testing and round the clock incident monitoring under the ISO 13485 incident procedure. Corsano says the platform complies with GDPR, HIPAA and ISO 27001.
No ISO 27001 certificate, SOC 2 report or outside penetration test is named.
The CardioWatch 287-2 System is cleared by the FDA for physiologic monitoring of adults who are not acutely ill, in hospitals, skilled nursing facilities and at home, under 510(k) clearances K232548 (March 2024) and K261367 (July 2026, which added sleep wake monitoring), and it is CE marked under the EU MDR. The cleared indications cover continuous pulse rate, oxygen saturation, skin temperature, movement and sleep, intermittent respiration rate, spot checks of blood pressure, lung function and weight, and multi parameter alarms, and Corsano runs an ISO 13485 quality management system.
Those clearances cover the wristband and its measurements, not Cor-EWS: neither mentions an early warning score, so the deterioration prediction layer sold on top of the cleared device is uncleared.
Interpretability is a stated design choice: hospitals can pick a Cor-EWS version with less machine learning, or run conventional early warning scores on the same data. The cuffless blood pressure algorithm was tested against international standards before clearance.
No governance process, monitoring for drift or performance by skin tone, age or condition is published for Cor-EWS.
Clinicians act on alerts rather than the system acting alone, and hospitals can fall back on conventional early warning scores computed from the same data. The cuffless blood pressure algorithm was tested against ISO 81060-2:2019, and Corsano monitors incidents around the clock under its ISO 13485 incident procedure.
No error rate for Cor-EWS, warranty or remediation commitment covers a missed or false alert.
Corsano says the wearable connects to hospital systems and feeds a hospital dashboard with continuous vital signs and early warning scores, and Medtronic places it in its acute care and monitoring portfolio, which connects devices across the hospital. Research partners can pull raw data through Corsano's data access service.
No EHR vendor, interface standard or production integration is named.
The CardioWatch streams to the Corsano Cloud on Amazon Web Services, with data clusters replicated across multiple availability zones, and results reach a hospital dashboard and connect to hospital systems. Research customers get a real time cloud research platform with raw data access.
Which AWS regions hold data for European and US customers is not stated.
Hospitals in the US buy the CardioWatch through Medtronic, its exclusive US distributor for hospital and hospital to home use, and elsewhere through Corsano and its distributors. Research and pharma customers have separate routes with raw data access and a cloud research platform.
Prices and contract terms are not published on either route.
General wards are the main hospital setting, with monitoring that follows the patient from pre operative optimization through discharge and into hospital at home and remote monitoring programs. Foch Hospital in Paris and Imelda Hospital in Antwerp are named users, and Medtronic distributes the device across US hospitals. Research settings include decentralized and hybrid clinical trials, pharma studies, eCOA and academic work.
Results are not reported by setting.
Pricing
Vendor-published figures are labeled as such. Figures labeled “Estimated” are derived from third-party sources and have not been confirmed by the vendor.
| Entry Price | Pricing Basis | BAA Tier | Implementation | Source |
|---|---|---|---|---|
|
Not published
|
Sold to US hospitals through Medtronic as exclusive distributor, and elsewhere through Corsano and distributors. No price or unit is published. | Corsano describes HIPAA compliance and runs on AWS as an AWS business associate; no customer business associate agreement is published. | Not published. Deployment includes CardioWatch wristbands, the Corsano Cloud and a hospital dashboard. | Vendor Published |
US hospitals buy through Medtronic, which distributes the CardioWatch exclusively for hospital and hospital to home use; research and pharma customers buy devices and data access separately. No device, subscription or per patient price is published.